Weekly Recap | Zai Lab -2.8%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Zai Lab (ZLAB) fell 2.8% this week to $24.98, while the S&P 500 added 1.21%, leaving the stock about 4.01 percentage points behind the benchmark. It opened Monday at $26.64 and touched a week high of $27.045, but momentum faded from there. Thursday brought a gap lower and a break below $25, with Friday sliding to $24.945 before a modest recovery. The week saw an 8.41% range and shrinking volume, with Friday’s turnover at just 299,900 shares.
The Week
Zai Lab (ZLAB) fell 2.8% this week to $24.98, while the S&P 500 added 1.21%, leaving the stock about 4.01 percentage points behind the benchmark. It opened Monday at $26.64 and touched a week high of $27.045, but momentum faded from there. Thursday brought a gap lower and a break below $25, with Friday sliding to $24.945 before a modest recovery. The week saw an 8.41% range and shrinking volume, with Friday’s turnover at just 299,900 shares. There was no major news catalyst; price settled below the 20-day moving average of $25.523.
Analyst Ratings
Among 12 brokers covering ZLAB, 9 rate it buy, 2 rate it overweight and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target of $33.14 sits roughly 32.67% above the $24.98 spot. Individual targets range widely from $24.25 to $50.00. ZLAB ranks 106th among 506 biotechnology names by analyst rating.
The Week Ahead
Macro data will set the tone for biotech risk appetite next week. Monday brings the Dallas Fed manufacturing business activity index, with a prior reading of 11.6. Tuesday includes FHFA house prices, the Case Shiller 20-city home price index, JOLTS job openings and consumer confidence, where the prior reading is 89.4 and the consensus is 90. ZLAB itself has no scheduled earnings or major events next week.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.